The Week Ahead: Hom...
Health Care: Drugs
Omeros Corporation (OMER: NASDAQ)
$5.14 0.05 | 0.98%
05/17/13 - 04:00 PM ET
Portfolios with OMER
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
Latest OMER Headlines from TheStreet
- 5 Stocks Insiders are Scooping Up 01.09.13 | 12:01 pm
- Top Insider Trades: FB LNKD SMM OMER 01.07.13 | 08:01 am
- Omeros Stock Gaps Down On Today's Open (OMER) 06.27.12 | 09:06 am
- 7 Stocks Soaring on Unusual Volume 06.08.12 | 04:06 pm
- 10 Stocks to Watch: Krispy Kreme, Omeros 04.01.11 | 01:04 pm
- Omeros Stock Gaps Down On Today's Open (OMER) 04.01.11 | 09:04 am
- Omeros, EXFO: After-Hours Trading 03.31.11 | 05:03 pm
- IPO Comeback In 2009 Sets Stage For Busy 2010 12.31.09 | 10:12 am
- Worst IPOs of 2009: Biggest Stock Flops 12.15.09 | 10:12 am
Press Releases for OMER
- Omeros Announces Closing Of $16.2 Million Registered Direct Offering Of Common Stock - PR Newswire 05.14.13 | 12:05 pm
- Omeros Announces $16.2 Million Registered Direct Offering Of Common Stock - PR Newswire 05.09.13 | 06:05 pm
- Omeros Requests Fast Track Designation For OMS824 For The Treatment Of Huntington's Disease - PR Newswire 05.01.13 | 07:05 am
- Omeros Ophthalmology Product OMS302 Granted Eligibility For European Centralized Review - PR Newswire 04.30.13 | 07:04 am
- Omeros Reports OMS302 Clinical Data Presented At The Annual ASCRS And ASOA Symposium And Congress - PR Newswire 04.25.13 | 07:04 am
- Omeros To Present At The 12th Annual Needham Healthcare Conference - PR Newswire 04.24.13 | 07:04 am
- Omeros To Present Additional OMS302 Clinical Data At The Annual ASCRS And ASOA Symposium And Congress - PR Newswire 04.19.13 | 07:04 am
- Omeros Files Orphan Drug Application For Treatment Of Atypical Hemolytic Uremic Syndrome With OMS721 - PR Newswire 04.17.13 | 07:04 am
- Omeros Announces That GPR17 Antagonists Improve Function In Model Of Multiple Sclerosis - PR Newswire 04.10.13 | 07:04 am
- Omeros Announces Positive OMS721 Data In Model Of Thrombotic Microangiopathy - PR Newswire 04.02.13 | 07:04 am
Partner Headlines for OMER
- Is This Biotech A Value Stock Or Value Trap? - Seeking Alpha 03.30.13 | 06:03 am
- Do You Have The Guts To Take On Cutting-Edge Biotech Like This VC? - Seeking Alpha 12.14.12 | 09:12 am
- From Earlier: Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program - Benzinga 10.02.12 | 09:10 am
- Netflix REITERATED Below Average and 3 Analyst-Reiterated Ratings Starting the Week - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- Market Wrap: Markets RALLY, Arena Makes HISTORY, Apple BEATS Samsung - Wall St. Cheat Sheet 06.28.12 | 09:06 am
- Ultimate Market Recap: News Corp. Makes Split Decision, RIM Looking Rough - Wall St. Cheat Sheet 06.28.12 | 08:06 am
- Omeros Eyeing Deals As Ophthalmology Drug Succeeds - Seeking Alpha 03.15.12 | 09:03 am
- UPDATE: Canaccord Upgrades Omeros; Raises PT - Benzinga 03.14.12 | 09:03 am
- UPDATE: Rodman & Renshaw Upgrades Omeros to Outperform - Benzinga 12.05.11 | 09:12 am
- A Bullish Speculative Options Bet and a Bearish One - Seeking Alpha 06.30.11 | 09:06 am
